Veramaris’s breakthrough innovation – an algal oil – will, for the first time, enable the production of the omega-3 fatty acids EPA and DHA for animal nutrition without using fish oil from wild-caught fish, a finite resource. DSM and Evonik announced their intention to start this joint venture in March 2017. Since then, all necessary approvals have been received.
Construction of the $ 200 million production facility at the Evonik site in Blair, Nebraska (United States), has commenced and is proceeding according to plan. Commercial quantities of the algal oil rich in the essential omega-3 fatty acids EPA and DHA will be ready for sale in 2019. Pilot quantities for market development purposes are already available. The initial annual production capacity will meet roughly 15% of the total current annual demand for EPA and DHA by the salmon aquaculture industry.
Sustainable and traceable source
Veramaris will be headed by CEO Karim Kurmaly and CFO Frank Beissmann. Marine biologist Kurmaly has been with DSM for more than 16 years, most recently as Vice President Animal Nutrition & Health in Asia Pacific. Beissmann, an engineer, has been with Evonik for more than 20 years and has held various positions in production, supply chain, marketing and controlling.
“Our algal oil, rich in both EPA and DHA, is our response to the industry’s call for a sustainable and traceable source of the omega3 fatty acids EPA and DHA. Veramaris will now enable our partners along the value chain to grow in a responsible way and meet the demand for healthy animal protein rich in both EPA and DHA for consumer health,” says Kurmaly.
